Fourth Quarter and Year Results Conference Call End 2011 Financial - - PDF document

fourth quarter and year results conference call end 2011
SMART_READER_LITE
LIVE PREVIEW

Fourth Quarter and Year Results Conference Call End 2011 Financial - - PDF document

Fourth Quarter and Year Results Conference Call End 2011 Financial February 27, 2012 Forward-looking Statements Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements, including, but


slide-1
SLIDE 1

Fourth Quarter and Year End 2011 Financial Results Conference Call

February 27, 2012

slide-2
SLIDE 2

1

Forward-looking Statements

Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements, including, but not limited to, statements regarding guidance with respect to integration-related activities, product candidates in development, timing of product launches and expected benefits from acquisitions by the Company. Forward-looking statements may be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “could,” “should,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and other risks and uncertainties detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date

  • f this presentation or to reflect actual outcomes.

Non-GAAP Information To supplement the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the Company uses non-GAAP financial measures that exclude certain items, such as amortization of inventory step-up, stock-based compensation step-up, restructuring and acquisition-related costsTBD, acquired in-process research and development ("IPR&D"), legal settlements, amortization and other non-cash charges, amortization of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest, loss on extinguishment of debt, and (gain) loss on investments, net, and adjusts tax expense to cash taxes. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a meaningful, consistent comparison of the company’s core operating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

slide-3
SLIDE 3

2

Agenda

  • 1. Fourth Quarter & Year End Results
  • 2. U.S. Dermatology Update
  • 3. Financial Update
slide-4
SLIDE 4

3

Fourth Quarter 2011 Results

Total Revenue = $688 million

34% revenue growth over 2010

Product sales = $654 million

34% product sales growth over 2010 10% organic product sales growth over 2010

Cash EPS = $0.94

88% Cash EPS growth over 2010

Adjusted Cash Flow from Operations = $253 million

22% adjusted cash flow from operations growth over 2010 Excluding changes in working capital - adjusted cash flow from

  • perations grew at >50% over 2010
slide-5
SLIDE 5

4

2011 Financial Summary

$0.62 $0.73 $0.54 $0.57 $0.94 $0.66 1st Qtr 2nd Qtr 3rd Qtr 4th Qtr

Reported Cash EPS Adjusted Cash EPS

Total 2011 Revenue = $2.46 Billion Total Cash EPS = $2.93

* Adjusted for Cloderm divestiture (Q1 2011) and Trobalt milestone (Q2 2011)

$529 $569 $565 $609 $601 $688 1st Qtr 2nd Qtr 3rd Qtr 4th Qtr

Reported Product Sales Adjusted Product Sales

slide-6
SLIDE 6

5

Strong Organic Growth

39%

  • 4%

14% 3%

7%

10%

Organic Growth

32%

  • 5%

13% 13% 10%

9%

Organic Growth

Fourth Quarter 2011 Full Year 2011

Branded Generics - LA Canada/ Australia U.S Neurology & Other U.S Dermatology

Total Organic Growth

Branded Generics - EU

slide-7
SLIDE 7

6

Adjusted Cash Flow From Operations

$253 $208 $260 $204

1st Qtr 2nd Qtr* 3rd Qtr 4th Qtr Excluded Items:

Total 2011 Adjusted Cash Flow from Operations = $925 Million

* Includes $40 M Milestone payment from GSK

  • Legal Settlements
  • Restructuring/Acquisition

Related Costs

  • Working Capital Changes
  • Tax Benefit from Stock Options
  • Effect of ASC 470-20
slide-8
SLIDE 8

7

2011 Performance v. Guidance

Original Expectations

Revenue $2.1-$2.3 billion Organic Growth ~8% Cash EPS $2.25 - $2.50 >$800 million in Adjusted

Cash Flow from Operations

Final Results

Revenue $2.46 billion Organic Growth 9% Cash EPS $2.93 $925 million in

Adjusted Cash Flow from Operations

slide-9
SLIDE 9

8

Deal Update

Completed in Q4 2011

Ortho Dermik Afexa iNova

Announced YTD 2012

Probiotica EyeTech

slide-10
SLIDE 10

9

Progress on 2012 Synergy Program

Run rate expected by mid-year Run Rate YTD

$200 million $135 million

slide-11
SLIDE 11

U.S. Dermatology Update

Rajiv De Silva

slide-12
SLIDE 12

11

U.S. Dermatology Integration Status

Completed Ongoing

Sales and Marketing Sales force optimization/restructuring Marketing combination A&P rationalization

  • R&D

Program rationalization People reduction

  • Supply Chain / Manufacturing

Supply agreements Long-term tech transfers

  • Finance

Order to cash

  • Information Technology

Commercial Manufacturing plant

slide-13
SLIDE 13

12

Maintaining Growth During Acquisitions in U.S. Dermatology

2011 vs. 2010 Volume Growth

Source: Wolters Kluwer Health; IRI Scan data; Retailer data

54% 25% 29% 27%

0% 10% 20% 30% 40% 50% 60% 70% Acanya Atralin Zovirax* CeraVe**

* Zovirax volume in TRx grams; **Cerave Scan Volume growth

slide-14
SLIDE 14

13

Acanya and Atralin Showing Sustained Prescription Volume Growth

10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 100,000 Q1 2009 Q2 2009 Q3 2009 Q4 2009 Q1 2010 Q2 2010 Q3 2010 Q4 2010 Q1 2011 Q2 2011 Q3 2011 Q4 2011 Acanya Atralin

Source: Wolters-Kluwer; Data for all prescribers

Revamping of Co-Pay Cards

slide-15
SLIDE 15

14

Promotional Efforts Turning the Elidel Growth Curve

  • 7%
  • 14%
  • 16%
  • 20%
  • 15%
  • 10%
  • 5%

0% FY 2011 Q4 2011 Jan-12

Elidel YOY TRx Growth All Prescribers

Source: Wolters Kluwer Health

Elidel YOY TRx Growth Dermatologists

9%

  • 2%
  • 7%
  • 10%
  • 5%

0% 5% 10% 15% FY 2011 Q4 2011 Jan-12

slide-16
SLIDE 16

15

Zovirax Franchise Rejuvenated Through New Strategy

Source: Wolters-Kluwer; Data for all prescribers

  • 5.0%

0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% 40.0% 45.0% 50.0%

Q1 2010 Q2 2010 Q3 2010 Q4 2010 Q1 2011 Q2 2011 Q3 2011 Q4 2011

TRx Grams vs. Prior year % Growth

  • 1%

12% 43% 47%

slide-17
SLIDE 17

16

70%

Driving CeraVe Growth Through New Product Introduction

Hydrating Cleanser Lotion Cream Facial PM Lotion AM Foaming Cleanser

+26% +27% +34% +101% +361% +332%

Original SKUs Newer SKUs

Proportion of Business 30%

Source: IRI Scan data; Retailer data

slide-18
SLIDE 18

17

U.S. Dermatology Pipeline Update

New Products Lifecycle Management Generics

# of Projects 4 ~15 3 ~20+

Onychomycosis (IDP-108) Psoriasis (IDP-118) Acne (IDP-107 / MC5) Acanya RAM Sculptra

Key Projects

Undisclosed

slide-19
SLIDE 19

Financial Update

Howard Schiller

slide-20
SLIDE 20

19

Financial Summary

* Excludes fair value step-up adjustment to inventory and other non-GAAP items

** Q410 & Q411 includes the impact of working capital changes of $22 million and $62 million respectively

Q4 2010 Q1 2011 Q2 2011 Q3 2011 Q4 2011 2011 Product Sales $489m $500m $530m $570m $654m $2,255m Total Revenue $515m $565m $609m $601m $688m $2,463m Cost of Goods Sold %* 31% 24% 29% 28% 25% 27% SG&A % 22% 21% 22% 21% 21% 21% R&D Expense $18m $14m $18m $18m $17m $66m Operating Margin (excluding amortization) 45% 50% 53% 50% 57% 51% Cash EPS $0.50 $0.62 $0.73 $0.66 $0.94 $2.93 Adjusted Cash Flow from Operations $187m** $204m $260m $208m $253m** $925m

slide-21
SLIDE 21

20

Segment Trends

Q4 10 Q4 11 FY 11 FY 12 e U.S. Dermatology 103.9 174.2 568.3 900-925 U.S. Neurology & Other 213.0 202.8 829.3 675-750 Canada/Australia 80.5 101.3 340.1 550-625 Branded Generics Latin America 69.0 65.8 254.9 >275 Branded Generics Europe 48.3 144.4 470.9 >625 South East Asia/South Africa N/A N/A N/A ~100 Emerging Markets N/A N/A N/A >1.0 B Total Revenue 514.6 $ 688.5 $ 2,463.5 $ $3.1 - $3.4 b

slide-22
SLIDE 22

21

Price vs. Volume Trend

4Q Price 4Q Volume 4Q Total 2011 Price 39%

  • 1%

8% 2% 1% 0%

  • 3%

14% 3% % 2011 Volume 33%

  • 12%

11% 12% 10% U.S. Neuro 8%

  • 11%
  • 4%

Branded Generics – Europe 0% 7% 10% Canada/ Australia 2% 2011 Total U.S. Derm

  • 6%

45% 12% 32% Branded Generics

  • LA

2% 1% 13% 13%

slide-23
SLIDE 23

22

COGS Trend

Q4 10 Q4 11 FY 11

U.S. Neuro & Other 24% 17% 17% U.S. Dermatology 35% 11% 15% Canada/Australia 28% 23% 28% Branded Generics - Europe 38% 47% 48% Branded Generics - Latin America 42% 37% 39%

Total 31% 25% 27%

slide-24
SLIDE 24

23

2011 Adjusted Cash Flow from Operations

$166 $59 $2,876 $2,653 $68 $164 $394 $925 $639

Current cash (2/24) position ~$570 m + $275 m undrawn revolver

Cash December 2010 Securities Repurchases Acquisitions Cap Ex Restructuring/ Integration/ Legal Settlements Other* Cash December 2011 Issuance LT Debt Adjusted CashFlow from Operations

* Includes payment of withholding tax upon vesting of share based awards, one-time working capital adjustments, proceeds from the

exercise of stock options and other miscellaneous cash outflows

slide-25
SLIDE 25

24

Currency Impact

Currency 2010 vs 2011 2012 YTD

Poland Serbia Hungary Russia Australia Canada Mexico Brazil South Africa

  • 16%
  • 4%
  • 17%
  • 5%
  • 2%
  • 13%
  • 13%
  • 22%

10% 1% 9% 9% 4% 2% 7% 9% 6%

  • Foreign currency per 1 U.S. Dollar
slide-26
SLIDE 26

25

Additional Updates

New Segment Reporting

U.S. Derm U.S. Neuro & Other Canada/Australia Emerging Markets

Number of Shares Outstanding

317 million diluted shares as of December 31, 2011

Decreased by 12 million shares from December 31, 2010

Strong Liquidity

Current cash position of ~$570 million $275 million undrawn revolver

Recent Financing

$600 million senior secured Tranche B Term Loan

LIBOR + 2.75% with 1% LIBOR floor

slide-27
SLIDE 27

Fourth Quarter and Year End 2011 Financial Results Conference Call

February 27, 2012